AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 81 min read$MRNA

Klinger Shannon Thyme sold $174K of MRNA

Klinger Shannon Thyme (Chief Legal Officer) sold 3,471 shares of Moderna, Inc. (MRNA) at $50.00 ($0.17M total) on 2026-06-04 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Klinger Shannon Thyme
Published Jun 8, 2026, 8:34 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 8, 2026, 8:38 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$MRNA
Neutral
high confidence
Mentioned
$MRNA
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MRNANeutralLow
01

Why it matters

The disclosure updates the record of insider ownership and may marginally influence sentiment, but the pre-arranged 10b5-1 structure reduces interpretability as a forward-looking negative signal.

02

Market read

A routine 10b5-1 open-market sale by a senior officer; no new company-specific catalyst is included.

03

What to watch

The article provides only the sale details; it does not state whether there were concurrent buys, option exercises, or broader insider activity around the same window.

Relevance 3/10Novelty 5/10Timing: Filed 2026-06-08; transaction dated 2026-06-04

Background

This is a SEC Form 4 insider transaction disclosure for Moderna, Inc., reported via EDGAR.

Company-level read

Ticker impact

$MRNANeutralHigh confidence
Context

Moderna insider Form 4 shows Chief Legal Officer Klinger Shannon Thyme sold 3,471 shares in an open-market transaction under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is a Form 4 insider sale, explicitly pre-arranged under Rule 10b5-1, with no accompanying operational/regulatory/financial catalyst described.

Market effects

Sector

Minimal—single-company insider sale without new clinical, regulatory, or financial information.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Even 10b5-1 sales can coincide with periods of elevated insider risk management; traders may still use it as a near-term sentiment check.

Key entities

  • issuer
    Moderna, Inc.

    MRNA, subject of the Form 4 insider transaction disclosure.

  • insider
    Klinger Shannon Thyme

    Chief Legal Officer who sold shares under a Rule 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

MRNA insider trading history →

Related articles

OCT 15
$MRNAMed

Moderna Stock Jumps 4.5% as Major Cancer Vaccine Catalyst Approaches

Moderna (MRNA) shares rose 4.5% as investors await detailed results from a Phase 3 cancer trial with Merck (MRK). The trial, involving 1,137 patients, showed the treatment reduced cancer recurrence. Results will be presented on October 24. Moderna reported a Q2 net loss of $782 million. Barclays estimates potential $3 billion annual melanoma sales by 2035, split equally with Merck.

tipranks.com6 min
OCT 15
$MRNAMed

Moderna (MRNA) Shares Surge on Cancer Vaccine Data Ahead of Late

Moderna (MRNA) shares rose 38% since late September ahead of a presentation on late-stage trial data for its cancer vaccine, developed with Merck (MRK). The rally follows a 170% surge after positive Phase 3 melanoma trial results in August. Moderna's P/S ratio is 41.76, significantly higher than its historical median of 8.48, reflecting market growth expectations despite its unprofitability. Insider activity shows no purchases and $64.6M in sales over the past year.

gurufocus.com6 min
OCT 15
$MRNAHigh

Moderna Stock Is Soaring on Cancer Vaccine Buzz. Is It Too Late to Get In?

Moderna's stock rose 658.2% year-to-date, reaching $223.60 premarket. The surge followed positive late-stage trial results for its cancer vaccine, developed with Merck. Analysts' price targets are below current levels, with a consensus at $122.67. Moderna reports Q3 earnings on November 6, with revenue and cash flow expectations to be revealed. The stock trades at 38.75 times trailing sales, raising valuation concerns.

247wallst.com2 min
OCT 15
$MRNAMed

MRNA Maintains Neutral Rating -- Price Target Raised to $137

Goldman Sachs maintained a Neutral rating on Moderna (MRNA) but raised its price target to $137 from $120. GuruFocus values MRNA at $23.84, suggesting it is 849.2% overvalued. The company has a GF Score of 54/100, with strengths in financial stability but weaknesses in profitability and valuation. Insider selling totaled $49.18M over the past three months.

gurufocus.com2 min
OCT 14
$MRNAHigh

MRNA Stock Surges On Cancer Vaccine Catalysts And Nasdaq-100 Move

Moderna Inc. (MRNA) shares rose 4.13% on October 14, 2026, driven by optimism around its mRNA cancer vaccine pipeline and inclusion in the Nasdaq-100 Index. The company reported $143M in revenue and a net loss of $782M for the latest quarter, with $5.1B in cash reserves. Analysts have adjusted price targets, with Bank of America raising its target to $200 and Morgan Stanley to $95, both maintaining cautious ratings. The next key catalyst is Moderna's Q3 2026 earnings report on November 6, 2026.

timothysykes.com3 min